Ohio State University Comprehensive Cancer Center
This is an observational study to collects blood samples and tumor tissue from adults with relapsed small-cell lung cancer (SCLC) receicing standard of care commercial DLL3 T cell engager. The goal of the study is to understand the changes in tumor markers over time and examine whether these changes are associated with clinical outcomes. Participants will provide blood samples and, when clinically feasible, tumor tissue during routine care visits, treatment, and imaging assessments. The study does not assign cancer treatment.
The goal of this study is to prospectively and longitudinally collect blood and tumor tissue from patients with relapsed small cell lung cancer (SCLC) receicing standard of care commercial DLL3 T cell engager. We will do a comprehensive multi-omic analysis integrating genomic, transcriptomic, proteomic, and clinical data to investigate mechanisms of resistance, and identify potential therapeutic vulnerabilities. Primary objective is to assess the feasibility of obtaining paired tumor samples and serial blood collection in relapsed ES-SCLC patients Secondary objectives are to characterize lon…
Inclusion Criteria: 1. 18 years of age or older 2. Confirmed pathologic diagnosis of active SCLC or neuroendocrine cancer. 3. Relapsed small cell lung cancer (SCLC) planning to receive commercial DLL3 bispecific T cell engager. 4. Willing to provide informed consent. 5. Willing to provide blood samples and undergo tissue biopsy at various time points throughout the study, collected in concurrence with treatment cycles and/or imaging visits 6. Patients with multiple primary malignancies, recurrent lung cancer, or mixed histology are not excluded. 7. Patients who have contraindications or are u…
Undergo blood and tissue sample collection
Arctuva estimate
Verify or correct the compensation shown for this listing.